Current stock page

Stock Analysis

Caris Life Sciences, Inc. (CAI) Stock Analysis

Caris Life Sciences, Inc. (CAI) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

CAI Stock Analysis Summary

Caris Life Sciences, Inc. (CAI) currently has an AIQ Score of 70/100, indicating a bullish setup. Momentum is the strongest factor at 85/100. Risk is the weakest current factor at 36/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

CAI at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$23.04
AIQ Score70/100
Overall ViewBullish
Technical Analysis ConsensusStrong Sell
Market Cap$6.54B
P/E Ratio (TTM)68.59
Forward P/E—
EPS (Q3 FY2026)$0.05
Revenue (Q3 FY2026)$275.36M
Dividend Yield (TTM)0.00%
Beta1.85
Volume3.02M
52-week range$14.19-$36.50
RSI 1430.87
50-Day SMA$29.39
200-Day SMA$21.63
Analyst Price Target$38.00
Next EarningsFeb 25, 2027
As of Nov 13, 2026 · Market close

CAICaris Life Sciences, Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 9/10
$23.04−$0.92 (−3.84%)

Latest quote

  • Momentum
    85
  • Value
    68
  • Quality
    71
  • Risk resilience
    36
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

CAI Stock Analysis Summary

Caris Life Sciences, Inc. (CAI) currently has an AIQ Score of 70/100, indicating a bullish setup. Momentum is the strongest factor at 85/100. Risk resilience is the weakest current factor at 36/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, CAI has AIQ Score of 70/100 with Momentum base of 85/100 and fading Risk resilience at 36/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (85/100) leads while Risk resilience (36/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -3.84% stock move · CAI classified in Biotechnology.

Current Evidence

BullishCAI is in a bullish AIQ regime; Momentum is the strongest visible factor at 85/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is CAI Bullish or Bearish Right Now?

CAI currently has a bullish overall setup. Momentum is the strongest factor at 85/100, while Risk Resilience is weakest at 36/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 71/100.
  • - Momentum is constructive at 85/100.
  • - Analyst target implies +64.93% upside from the latest quote.
Bear Case
  • - Risk Resilience is weak at 36/100.
  • - Technical consensus has more sell votes than buy votes (35 vs 7).

Current Consensus

CAI's Technical Analysis Consensus is currently Strong Sell, with 7 buy, 4 neutral, and 35 sell votes. CAI's 14-day RSI is 30.87, which places the stock in a weaker momentum range. CAI's beta is 1.85, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in CAI?

The largest recent change in CAI is Momentum moving down by 3.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
-2.0
Momentum
-3.0
Quality
-1.0
Risk
-1.0

What Would Change the CAI Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

CAI Decision Framework

Public evidence layers, setup checks, and risk context for Caris Life Sciences, Inc..

Caris Life Sciences, Inc. (CAI) Stock Analysis

Caris Life Sciences, Inc. has an AIQ Score of 70/100 in a Bullish regime. Momentum is strongest at 85/100. Beta is 1.85, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextCAI is in a Bullish AIQ regime with score 70/100.
Signal ConflictThe primary conflict is that momentum leads at 85/100 while risk lags at 36/100.
Factor EvidenceMomentum 85/100 · Value 68/100 · Quality 71/100 · Risk 36/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 85/100.

TimingPass

Momentum is 85/100 and RSI (14) is 30.9.

Regime fitPass

CAI is in a Bullish regime at 70/100.

Risk controlFail

Risk factor is 36/100 with beta 1.85 and annual volatility 69.82%.

ConflictWait

Current conflict: momentum leads at 85/100 while risk lags at 36/100.

AIQ Score
70/100
Price
$23.04
Beta
1.85
RSI (14)
30.9

CAI Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

CAI Fundamentals

CAI valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$275.36M
Net income
$15.25M
Free cash flow
-$39.72M
View full CAI fundamental analysis

CAI Technical Analysis

CAI technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
30.87
Price vs SMA-50
-21.60%
View full CAI technical analysis

CAI Stock Catalysts

Track CAI earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 25, 2027
Analyst target
$38.00
News items
0
View CAI earnings and stock catalysts

CAI Dividend Analysis

CAI dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View CAI dividend history and analysis

CAI Financial Data

CAI revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$275.36M
EPS
$0.05
Periods
8
View CAI financials

CAI Risk Analysis

CAI volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.85
Risk score
36/100
1Y volatility
69.82%
View CAI risk analysis

CAI Stock News

CAI stock news, market tone, recent headlines, and catalyst context.

News items
0
Updated
—
Sentiment
—
Read CAI stock news

CAI vs Biotechnology Peers

Current peer cohort: CAI · CAPR · CELC · CGON · CLDX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
CAI
Current stock
70/10068/10085/10036/1000.2269.82%Current
CAPR
Capricor Therapeutics, Inc.
38/100—45/10016/1000.93395.16%CAI vs CAPR
CELC
Celcuity Inc.
41/100—24/10034/100-0.1963.58%CAI vs CELC
CGON
CG Oncology Inc.
59/100—71/10059/1001.3858.41%CAI vs CGON
CLDX
Celldex Therapeutics, Inc.
43/100—48/10055/1000.5552.44%CAI vs CLDX
Pairwise Compare links: CAPR · CELC · CGON · CLDXCAI vs CAPRCAI vs CELCCAI vs CGONCAI vs CLDXCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a CAI stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for CAI: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
68.59
As of Nov 13, 2026
Revenue growth
26.99%
Gross margin
69.09%
Current debt / equity
0.72
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$275.36M
Quarter net income
$15.25M
Quarter free cash flow
-$39.72M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bearish
RSI 14
30.87
MACD
-1.63

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
36/100
Beta
1.85
Annual volatility
69.82%
Max drawdown
-49.58%

CAI Stock FAQ

What is CAI stock price today?

Caris Life Sciences, Inc.'s current stock price is $23.04. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is CAI bullish or bearish right now?

CAI's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is CAI's market cap?

CAI's market cap is $6.54B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is CAI's current P/E ratio?

CAI's current P/E ratio is 68.59 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is CAI's RSI?

CAI's 14-day RSI is 30.87 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is CAI above its 50-day and 200-day moving averages?

CAI is -21.60% from its 50-day SMA and 6.51% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is CAI's next earnings date?

CAI's next earnings date is currently listed as Feb 25, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does CAI pay a dividend?

CAI's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.